Refer attached document

Revenue declinedNet loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.7%Reaction day

₹150.00

prior close

₹136.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-6.3% vs market

Pharmaceuticals peers, median of 160sector-0.1%-6.6% vs sector

On the reaction day the stock moved 6.3 pts less than Nifty Microcap 250 and 6.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.0

10m

-4.1

15m

-4.8

30m

-4.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.7-0.4-6.3-0.1-6.6

Next day

-10.6-1.7-8.9-0.9-9.8

-11.3-1.3-10.1-0.2-11.1

-11.3-0.7-10.6+0.3-11.7

-3.7+0.4-4.1+1.1-4.7

-3.3+0.5-3.8+0.2-3.5

-0.1+2.8-2.9+1.0-1.0

15d

-0.3+1.2-1.5-0.2-0.1

+0.7+5.3-4.6+1.7-1.0

-4.7+9.9-14.6+7.9-12.6

+28.5+13.1+15.4+7.6+21.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanjivani Paranteral Ltd reported FY2026 standalone revenue of Rs 6,476.39 Lacs, down 7.6% from Rs 7,009.86 Lacs in FY2025. Net profit fell to Rs 692.32 Lacs from Rs 810.18 Lacs (down ~14.5%), with EPS at Rs 5.67 vs Rs 6.89 prior year. Consolidated revenue was Rs 6,866.57 Lacs with net profit of Rs 669.38 Lacs (down ~17.3%). Q4 performance was impacted by temporary shipment delays (~Rs 6 crore goods undispatched due to geopolitical disruptions) and unfavourable product mix pressuring EBITDA margins. Two new plants (Pune IV fluids and Prague) are in early commercialisation stages. Auditors R.B. Gohil & Co. issued an unmodified (clean) opinion. The company also raised equity capital during the year (share capital increased from Rs 1,188.17 Lacs to Rs 1,228.43 Lacs).

Likely market impact

Revenue and profit both declined year-on-year, indicating pressure on margins and operational challenges from geopolitical disruptions and new plant ramp-up costs. Short-term borrowings surged significantly (standalone 7x to Rs 248.14 Lacs; consolidated 2x to Rs 571.39 Lacs), suggesting increased reliance on debt. The clean audit opinion provides some comfort, but the negative operating cash flow (-Rs 155.25 Lacs standalone) is a concern for investors.